Nicox (LTS:0RCQ) Net Change in Cash : €-8.64 Mil (TTM As of Jun. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Nicox Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Nicox's Net Change in Cash for the six months ended in Jun. 2024 was €0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was €-8.64 Mil.

Nicox Net Change in Cash Historical Data

The historical data trend for Nicox's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Net Change in Cash Chart

Nicox Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

6.04

19.09

-5.23

-14.32

Nicox Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Net Change in Cash	Get a 7-Day Free Trial															-10.33	-3.99	-8.64	-	-

Nicox Net Change in Cash Calculation

Nicox's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	0	+	0	+	0	+	0
	=	0.00

Nicox's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0 + 0 + 0 + 0

= 0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-8.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nicox Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Nicox's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » Net Change in Cash

Comparable Companies

XPAR:ALVAL XPAR:AELIS XPAR:ALDVI XPAR:ALNFL XPAR:POXEL XPAR:ALPAT XPAR:ALVIO XPAR:ALVET XPAR:ALTAO XPAR:ALGEN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX

Traded in Other Exchanges

NICXF:USA ALCOX:France NXOA:Germany

Address

Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410

Website

https://www.nicox.com

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines